Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP

Ruth Pettengell, Antonio Salar Silvestre, Matthias Schwenkglenks, Francesca Gaia Rossi, Ulrich Duehrsen, Gregor Verhoef, Pieternella Johanna Lugtenburg, Tracey Wheeler, Beatriz Pujol, Corinne Haioun

Research output: Contribution to journalArticle

Abstract

IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9 weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89 patients with Hb concentrations

Original languageEnglish
Pages (from-to)26-29
Number of pages4
JournalHematology
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Anemia
  • Chemotherapy
  • Darbepoetin alfa
  • Erythropoietin-stimulating agents
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP'. Together they form a unique fingerprint.

  • Cite this

    Pettengell, R., Silvestre, A. S., Schwenkglenks, M., Rossi, F. G., Duehrsen, U., Verhoef, G., Lugtenburg, P. J., Wheeler, T., Pujol, B., & Haioun, C. (2013). Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP. Hematology, 18(1), 26-29. https://doi.org/10.1179/1607845412Y.0000000033